Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | ESRRA | P11474 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 11/20 | 0.50 |
| ▸ | PGR | P06401 | 2/20 | 0.49 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.47 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.47 |
| ▸ | IDH1 | O75874 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5656320 | 0.89 | AR (0.50) | ALDH1A1KDM4EUSP2ESRRAAR | |
| SCHEMBL7168165 | 0.88 | ALDH1A1 (0.54) | ALDH1A1KDM4EUSP2ESRRAAR | |
| SCHEMBL12151755 | 0.85 | AR (0.52) | AR | |
| SCHEMBL29546917 | 0.85 | AR (0.52) | AR | |
| SCHEMBL10267017 | 0.84 | ALDH1A1 (0.58) | ALDH1A1KDM4EUSP2ARIMPDH2 | |
| SCHEMBL12818198 | 0.83 | AR (0.45) | ESRRAAR | |
| SCHEMBL30313130 | 0.82 | XDH (0.48) | ALDH1A1ESRRAAR | |
| SCHEMBL16952914 | 0.82 | L3MBTL1 (0.44) | KDM4EESRRARAB9AL3MBTL1 | |
| SCHEMBL2526268 | 0.82 | AR (0.53) | ESRRAARPGR | |
| SCHEMBL11461499 | 0.81 | SCN9A (0.56) | ARRAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210155593-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | REGENACY PHARMACEUTICALS LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-20210155593-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | REGENACY PHARMACEUTICALS LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-10858323-B2 | HDAC inhibitors for the treatment of diabetic peripheral neuropathy | REGENACY PHARMACEUTICALS, LLC (US) | 2020-12-08 | — | — | US | disclosed |
| US-10858323-B2 | HDAC inhibitors for the treatment of diabetic peripheral neuropathy | REGENACY PHARMACEUTICALS, LLC (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190106392-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | ACETYLON PHARMACEUTICALS, INC. | 2019-04-11 | — | — | US | disclosed |
| US-20190106392-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | ACETYLON PHARMACEUTICALS, INC. | 2019-04-11 | — | — | US | disclosed |
| EP-3368026-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | Acetylon Pharmaceuticals, Inc. (US) | 2018-09-05 | — | — | EP | disclosed |
| US-10040769-B2 | HDAC inhibitors for the treatment of diabetic peripheral neuropathy | REGENACY PHARMACEUTICALS, LLC (US) | 2018-08-07 | — | — | US | disclosed |
| US-10040769-B2 | HDAC inhibitors for the treatment of diabetic peripheral neuropathy | REGENACY PHARMACEUTICALS, LLC (US) | 2018-08-07 | — | — | US | disclosed |
| WO-2017075192-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | ACETYLON PHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| EP-2380885-A1 | Guanidine compounds and use of same as binding partners for 5-HT5 receptors | Abbott GmbH & Co. KG (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-20110237589-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2011-09-29 | — | — | US | disclosed |
| EP-2366392-A1 | Guanidine compounds and use of same as binding partners for 5-HT5 receptors | Abbott GmbH & Co. KG (DE) | 2011-09-21 | — | — | EP | disclosed |
| EP-2366697-A1 | Guanidine compounds and use of same as binding partners for 5-HT5 receptors | Abbott GmbH & Co. KG (DE) | 2011-09-21 | — | — | EP | disclosed |
| US-20070299074-A1 | Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2007-12-27 | — | — | US | disclosed |
| EP-1716127-A2 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | Abbott GmbH & Co. KG (DE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005082871-A2 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT GMBH & CO. KG (DE) | 2005-09-09 | — | — | WO | disclosed |
| US-6362372-B2 | HYDROGENATION OF A TRIFLUOROBENZYLNITRILE BY HYDROGEN IN AN ORGANIC SOLVENT IN THE PRESENCE OF AMMONIA AND A CATALYST COMPRISING A PLATINUM GROUP ELEMENT; EXTREMELY HIGH YIELDS | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-03-26 | — | — | US | disclosed |
| US-20020007086-A1 | Process for producing trifluoromethylbenzylamines | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-01-17 | — | — | US | disclosed |
| US-6175041-B1 | HYDROGENATING A TRIFLUOROMETHYLBENZONITRILE WITH HYDROGEN IN AN ORGANIC SOLVENT IN THE PRESENCE OF AMMONIA, USING A RANEY CATALYST | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007086-A1 | Process for producing trifluoromethylbenzylamines | IDH1, INMT, TH | ALDH1A1 1093/4885KDM4E 1350/4885USP2 958/4885 |
| US-20210155593-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | HDAC4, HDAC5, HDAC9 | ALDH1A1 633/4885KDM4E 113/4885USP2 1487/4885 |
| US-10040769-B2 | HDAC inhibitors for the treatment of diabetic peripheral neuropathy | HDAC4, HDAC5, HDAC9 | ALDH1A1 633/4885KDM4E 113/4885USP2 1487/4885 |
| US-20190106392-A1 | HDAC INHIBITORS FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHY | HDAC4, HDAC5, HDAC9 | ALDH1A1 633/4885KDM4E 113/4885USP2 1487/4885 |
| US-10858323-B2 | HDAC inhibitors for the treatment of diabetic peripheral neuropathy | HDAC4, HDAC5, HDAC9 | ALDH1A1 633/4885KDM4E 113/4885USP2 1487/4885 |
| US-20070299074-A1 | Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors | HTR5A, GRM5, TAAR5 | ALDH1A1 2830/4885KDM4E 2684/4885USP2 4025/4885 |
| US-20110237589-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, TAAR5 | ALDH1A1 2830/4885KDM4E 2684/4885USP2 4025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.